A Brain Scan May Predict Alzheimer’s. Should You Get One?


Juli Engel was delighted when a neurologist really useful a PET scan to find out whether or not amyloid — the protein clumps related to an elevated threat of Alzheimer’s illness — was accumulating in her mom’s mind.

“My internal response was, ‘Yay!’” mentioned Ms. Engel, 65, a geriatric care supervisor in Austin, Tex., who has been making virtually month-to-month journeys to assist her mom in Florida. “He’s using every tool to try to determine what’s going on.”

Sue Engel, who’s 83 and lives in a retirement group in Leesburg, Fla., has been experiencing reminiscence issues and different indicators of cognitive decline for a number of years. Her daughter checked off the warning indicators: her mom has been financially exploited, suffered an insurance coverage rip-off, induced an auto accident.

Medicare officers determined in 2013, shortly after PET (positron emission tomography) amyloid imaging grew to become out there, that they lacked proof of its well being advantages. So outdoors of analysis trials, Medicare doesn’t cowl the scans’ substantial prices ($5,000 to $7,000, the Alzheimer’s Association says); non-public insurers don’t, both.

Results from a different approach, an infusion drug being tested in older people with amyloid but without cognitive impairment, remain several years away.

“As a clinician, would I like amyloid information about my symptomatic patients? Yes,” said Dr. Ronald Petersen, a neurologist and director of the Mayo Clinic Alzheimer’s Disease Research Center. “Am I going to be able to do something about it? Not at present.”

The drugs approved for Alzheimer’s, primarily Aricept and Namenda, have modest benefits in some patients for a limited time. Neither has been shown effective for mild cognitive impairment, often a precursor to dementia.

Yet a recently published study, undertaken to provide Medicare with more information in hopes of reversing its reimbursement decision, shows that positive amyloid PET scans lead to far greater use of these and other medications.

The Ideas study (the name is shorthand for “Imaging Dementia — Evidence for Amyloid Scanning”) analyzed the treatment of 11,409 Medicare beneficiaries with mild cognitive impairment or dementia (average age: 75) nationwide. PET scans detected amyloid in 55 percent of the patients with mild impairment and 70 percent of those with dementia; those results influenced their cases in several ways.

The biggest change: soaring prescriptions. About 40 percent of those with mild impairment had been taking Alzheimer’s drugs; after a PET scan that detected amyloid plaques, the proportion more than doubled. In those with dementia, use of dementia drugs climbed from 63 to 91 percent after a positive PET scan.

Stopping those drugs after a negative scan happened far more rarely, “a very common dynamic in medicine,” Dr. Langa pointed out. “Once a treatment is started, it’s hard to stop it.”

The second round of the Ideas study will assess whether these changes led to better health. Were patients less likely to go to emergency rooms or to be hospitalized? Did costs rise or fall?

The researchers expect to publish those findings early next year. If they show that patients benefited, the Alzheimer’s Association will ask Medicare to reconsider its earlier decision and cover PET scans for the subset of patients with atypical or unexplained symptoms.

Those questioning broader access worry, however, about “indication creep,” when a drug or test approved for patients with a particular condition becomes used for others. They also worry about crushing costs for Medicare.

“Even if a scan cost zero dollars, I wouldn’t recommend it,” said Dr. Ken Covinsky, a geriatrician at the University of California, San Francisco. “Do you really want to know that you have amyloid in your brain, years ahead of cognitive problems that may never develop?”

Proponents of making PET scans more widely available argue that knowing their amyloid status may motivate patients to make lifestyle changes. Stopping smoking, exercising and eating more healthily are all found to reduce dementia, even among those at higher genetic risk. Perhaps, too, patients will be more likely to begin advance care planning.

“Those are good things to do whether you have amyloid or not,” Dr. Covinsky argued.

For now, costs probably prevent many people from seeking PET scans for diagnosis. If Medicare will pay — and possibly even if it won’t — more patients may find ways to be scanned.

“You’ll always have people who use it inappropriately, but hopefully we can keep that to a minimum” by educating doctors, said Maria Carrillo, chief science officer at the Alzheimer’s Association.

But ultimately, “we’re not here to tell people what to do,” she added. “There are people who really want that validation, and that’s a personal decision.”

Juli Engel may be among them.

Once the neurologist documents her mother’s incapacity, she can take steps to prevent Sue Engel from driving, and to move her into assisted living when needed. As a geriatric care manager, “I know the trajectory of this disease,” she said.

Because she also knows that both her maternal grandparents had Alzheimer’s, she is considering her own future, too. Does she have amyloid in her brain?

Her family is full of scientists, and “it’s our bent to want to know these things,” she said. “I think we’re entitled to that.”



Source link Nytimes.com

Get more stuff like this

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.